Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06334120
Other study ID # 20654
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 30, 2024
Est. completion date March 31, 2026

Study information

Verified date May 2024
Source Bayer
Contact Bayer Clinical Trials Contact
Phone (+)1-888-84 22937
Email clinical-trials-contact@bayer.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels. This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth. To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants. During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors. Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 600
Est. completion date March 31, 2026
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender Male
Age group 19 Years and older
Eligibility Inclusion Criteria: - Male aged =19 years - Patients with high risk nmCPRC - Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dL]) - Patients with mHSPC - histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography(CT), or magnetic resonance imaging (MRI). - be candidates for androgen-deprivation therapy and docetaxel - Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice - Written informed consent from subject or legal representative; assent from subject when appropriate Exclusion Criteria: - Patients participating in an investigational program with interventions outside of routine clinical practice - Participants with contraindication according to the locally approved prescribing information

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Darolutamide (Nubeqa, BAY1841788)
The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Locations

Country Name City State
Korea, Republic of Multiple locations Multiple Locations

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number, severity of adverse events (including SAEs) SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment. From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Primary Number, severity of adverse drug reactions (including SADRs) SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide. From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Primary The outcome of (serious) adverse events An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment. From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Primary The outcome of (serious) adverse drug reactions An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide. From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Secondary Metastasis-free survival (MFS) MFS is defined as the time (months) from the initiation of Darolutamide treatment to the date of first observed metastasis. Up to 52 weeks
Secondary Time to symptomatic skeletal event (SSE) Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event. Up to 52 weeks
Secondary Time to prostate-specific antigen (PSA) progression Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at =25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of =2 ng/mL above nadir. Up to 52 weeks
Secondary Number of patients with metastasis of castration-resistant prostate cancer (mCRPC) Time to mCRPC, defined as the time to PSA progression with serum testosterone being at castrate level <0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions, whatever comes first. Up to 52 weeks
Secondary Overall survival Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause. Up to 52 weeks
Secondary Duration of Darolutamide treatment Duration of Darolutamide treatment is defined as the time (months) from the start of Darolutamide treatment to the day of permanent discontinuation of Darolutamide (including death). Up to 52 weeks
Secondary Reasons for ending Darolutamide Up to 52 weeks
Secondary Dosage and dose modification of Darolutamide Up to 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT05381311 - Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Active, not recruiting NCT00309985 - Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Phase 3
Completed NCT03532217 - Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer Phase 1
Active, not recruiting NCT05059236 - A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. Phase 2
Completed NCT02799602 - Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer Phase 3
Not yet recruiting NCT06134271 - Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer Phase 2
Active, not recruiting NCT04934722 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension Phase 3
Recruiting NCT05901649 - A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Not yet recruiting NCT06452212 - Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
Withdrawn NCT03343977 - Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase 1/Phase 2
Active, not recruiting NCT04191096 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Phase 3
Active, not recruiting NCT03879122 - A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer Phase 2/Phase 3